<DOC>
	<DOCNO>NCT00546143</DOCNO>
	<brief_summary>This study evaluate safety efficacy omalizumab asthma attack mild moderate allergic asthma</brief_summary>
	<brief_title>Safety Tolerability Omalizumab Patients With Mild Moderate Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosis allergic asthma &gt; = 1 year duration history consistent Step 2 3 clinical feature Global Initiative Asthma guideline . Eligible baseline serum immunoglobulin E ( IgE ) level value bodyweight combination Documented medical history anaphylaxis Lung disease mild moderate allergic asthma chronic obstructive pulmonary disease ( COPD ) Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Asthma , anti-immunoglobulin E , omalizumab</keyword>
</DOC>